• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Alcohol Abstinence: Campral Now FDA-Approved

Article

Acamprosate calcium (Campral)from Lipha Pharmaceuticals, Inc,has been approved by the FDAfor the treatment of alcohol-dependentpersons who wish to remain alcohol-free after they have stoppeddrinking. Although its mechanismof action is not fully understood,this drug was shown to be more effectivethan placebo in maintainingabstinence. Acamprosate is nonaddictiveand has been shown to bewell tolerated in clinical trials. Themost common adverse effects areheadache, diarrhea, flatulence, andnausea.

New Drug to MaintainAlcohol AbstinenceAcamprosate calcium (Campral)from Lipha Pharmaceuticals, Inc,has been approved by the FDAfor the treatment of alcohol-dependentpersons who wish to remain alcohol-free after they have stoppeddrinking. Although its mechanismof action is not fully understood,this drug was shown to be more effectivethan placebo in maintainingabstinence. Acamprosate is nonaddictiveand has been shown to bewell tolerated in clinical trials. Themost common adverse effects areheadache, diarrhea, flatulence, andnausea.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.